BIOMAT Database Logo BIOMAT Database Logo

Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. 2003

B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Department of Neuropsychiatry of Childhood and Adolescence, University of Vienna, Vienna, Austria. barbara.kornek@univie.ac.at

BACKGROUND Recent data indicate that in multiple sclerosis disease onset before the age of 16 is more common than previously assumed. However, current therapeutic options are limited to the treatment of acute attacks in these patients. Glatiramer acetate has been successfully applied in adults with relapsing-remitting multiple sclerosis, but there are no data available about the use of glatiramer acetate in childhood and juvenile onset multiple sclerosis. METHODS Seven patients with relapsing-remitting multiple sclerosis and disease onset between 9 and 16 years of age were treated with daily subcutaneous injection of 20 mg glatiramer acetate (Copaxone). Patients were followed for 24 months. Treatment was initiated in all patients before the age of 18. RESULTS The use of glatiramer acetate in our cohort of early onset multiple sclerosis patients was safe and well tolerated. Two out of seven patients remained relapse-free during the two year period. Clinical disability as measured by the EDSS remained stable in three out of seven patients. CONCLUSIONS Due to the small number of patients the efficacy of the treatment has to be interpreted with caution. However, there might be a more pronounced treatment benefit in patients with low disability at treatment initiation and early treatment onset.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004172 Diplopia A visual symptom in which a single object is perceived by the visual cortex as two objects rather than one. Disorders associated with this condition include REFRACTIVE ERRORS; STRABISMUS; OCULOMOTOR NERVE DISEASES; TROCHLEAR NERVE DISEASES; ABDUCENS NERVE DISEASES; and diseases of the BRAIN STEM and OCCIPITAL LOBE. Double Vision,Polyopsia,Diplopia, Cortical,Diplopia, Horizontal,Diplopia, Intermittent,Diplopia, Monocular,Diplopia, Refractive,Diplopia, Unilateral,Diplopia, Vertical,Cortical Diplopia,Cortical Diplopias,Diplopias,Diplopias, Cortical,Diplopias, Horizontal,Diplopias, Intermittent,Diplopias, Monocular,Diplopias, Refractive,Diplopias, Unilateral,Diplopias, Vertical,Horizontal Diplopia,Horizontal Diplopias,Intermittent Diplopia,Intermittent Diplopias,Monocular Diplopia,Monocular Diplopias,Polyopsias,Refractive Diplopia,Refractive Diplopias,Unilateral Diplopia,Unilateral Diplopias,Vertical Diplopia,Vertical Diplopias,Vision, Double
D004185 Disability Evaluation Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits. Disability Evaluations,Evaluation, Disability,Evaluations, Disability
D005074 Evoked Potentials, Visual The electric response evoked in the cerebral cortex by visual stimulation or stimulation of the visual pathways. Visual Evoked Response,Evoked Potential, Visual,Evoked Response, Visual,Evoked Responses, Visual,Potential, Visual Evoked,Potentials, Visual Evoked,Response, Visual Evoked,Responses, Visual Evoked,Visual Evoked Potential,Visual Evoked Potentials,Visual Evoked Responses

Related Publications

B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate.
March 2001, Journal of neurology, neurosurgery, and psychiatry,
B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
[Interferon-beta treatment in patients with childhood-onset and juvenile multiple sclerosis].
January 2004, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Glatiramer acetate in multiple sclerosis.
July 2005, Expert review of neurotherapeutics,
B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
February 2004, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Glatiramer acetate in the treatment of multiple sclerosis.
February 2005, Neurologic clinics,
B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Glatiramer acetate in the treatment of multiple sclerosis.
July 2001, Expert opinion on pharmacotherapy,
B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Glatiramer acetate in the treatment of multiple sclerosis.
April 2007, Neuropsychiatric disease and treatment,
B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients.
February 2002, Journal of neuroimmunology,
B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Glatiramer acetate for multiple sclerosis.
June 2001, Drug and therapeutics bulletin,
B Kornek, and G Bernert, and C Balassy, and J Geldner, and D Prayer, and M Feucht
Glatiramer acetate for multiple sclerosis.
May 2010, The Cochrane database of systematic reviews,
Copied contents to your clipboard!